Drug Trial Radar · NCT04187443
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jun 2, 2020
Primary completion
Oct 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Fountain Medical Development Co., Ltd.
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Conditions
- Diabetic Macular Edema
- Macular Edema
- Type 2 Diabetes With Diabetic Macular Edema
- Type 1 Diabetes With Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
MS-553Drug
MS-553
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse eventsTime frame: Baseline to Day 56
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.